Prescription medicine
Marstacimab Brand names: Hympavzi
Marstacimab (Hympavzi) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the marstacimab FDA label on DailyMed (effective June 22, 2026); every marstacimab label on DailyMed.
Highlights of the record
FDA label of June 22, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:
hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or
hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors.
Forms and strengths
- 75 mg/.5ml
- 150 mg/ml
Injection (solution).
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 84 through July 30, 2026
What is marstacimab used for?
From the label: indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with:
hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors, or
hemophilia B (congenital factor IX deficiency) with or without factor IX inhibitors. […]
Source: FDA drug label (HYMPAVZI), Pfizer Laboratories Div Pfizer Inc, effective June 22, 2026 (SPL set a2cc631e-13a6-40c2-acf9-065ccedfb90a), via openFDA; the full label on DailyMed
Is there a generic for marstacimab (Hympavzi)?
No generic marstacimab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for marstacimab?
The FDA Adverse Event Reporting System holds 84 reports that list marstacimab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1 are coded as a death and 15 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Marstacimab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other